Journal article

Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial

Patrick Bowden, Andrew W See, Mark Frydenberg, Hodo Haxhimolla, Anthony J Costello, Daniel Moon, Paul Ruljancich, Jeremy Grummet, Alan Crosthwaite, Ganes Pranavan, Justin S Peters, Kevin So, Stella M Gwini, Dean P McKenzie, Skye Nolan, Lloyd ML Smyth, Craig Everitt



Stereotactic body radiotherapy (SBRT) can delay escalation to systemic treatment in men with oligometastatic prostate cancer (PCa). However, large, prospective studies are still required to evaluate the efficacy of this approach in different patient groups. This is the interim analysis of a prospective, single institution study of men relapsing with up to five synchronous lesions following definitive local treatment for primary PCa. Our aim was to determine the proportion of patients not requiring treatment escalation following SBRT. In total, 199 patients were enrolled to receive fractionated SBRT (50 Gray in 10 fractions) to each visible lesion. Fourteen patients were castration resistant ..

View full abstract